Trial Profile
A First-in-Man study on intratumoral administration of P28R
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Dec 2018
Price :
$35
*
At a glance
- Drugs Peptides (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; First in man
- 09 Dec 2018 New trial record
- 28 Nov 2018 According to a CanImguide Therapeutics media release, the company recently initiated this study in Sweden.